

## Aurora Health Care, Inc. and Affiliates

Consolidated Financial Statements as of and for the Years Ended December 31, 2017 and 2016, and Independent Auditors' Report

#### TABLE OF CONTENTS

	Page
INDEPENDENT AUDITORS' REPORT	2
CONSOLIDATED FINANCIAL STATEMENTS AS OF AND FOR THE YEARS ENDED DECEMBER 31, 2017 AND 2016:	
Balance Sheets	3 - 4
Statements of Operations and Changes in Unrestricted Net Assets	5
Statements of Changes in Net Assets	6
Statements of Cash Flows	7 - 8
Notes to Consolidated Financial Statements	9 - 43

## Deloitte.

Deloitte & Touche LLP 555 E. Wells St. Ste. 1400 Milwaukee, WI 53202 USA

Tel: +1-414-271-3000 www.deloitte.com

#### **INDEPENDENT AUDITORS' REPORT**

To the Board of Directors of Aurora Health Care, Inc.:

We have audited the accompanying consolidated financial statements of Aurora Health Care, Inc. and Affiliates ("Aurora"), which comprise the consolidated balance sheets as of December 31, 2017 and 2016, and the related consolidated statements of operations and changes in unrestricted net assets, changes in net assets, and cash flows for the years then ended, and the related notes to the consolidated financial statements.

#### Management's Responsibility for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

#### Auditors' Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to Aurora's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of Aurora's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

#### Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Aurora Health Care, Inc. and Affiliates as of December 31, 2017 and 2016, and the results of their operations, changes in their net assets, and their cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Deloitte is Touche LLP

March 29, 2018

#### CONSOLIDATED BALANCE SHEETS AS OF DECEMBER 31, 2017 AND 2016 (In thousands)

ASSETS	2017	2016
CURRENT ASSETS:		
Cash and cash equivalents	\$ 192,883	\$ 107,664
Investments	1,834,050	1,614,843
Assets whose use is limited or restricted	5,059	5,484
Patient accounts receivable — net of allowance for doubtful accounts of \$105,128 and \$97,349 in 2017 and		
2016, respectively	715,431	731,746
Other receivables	84,939	102,791
Inventory	69,583	70,031
Prepaids and other current assets	57,030	48,026
Estimated third-party payor settlements	13,910	9,989
Total current assets	2,972,885	2,690,574
ASSETS WHOSE USE IS LIMITED OR RESTRICTED:		
Board-designated and other	184,087	164,168
Contractually-restricted	179,841	154,267
Donor restricted	61,104	53,821
Debt service reserve	19,089	25,792
Total assets whose use is limited or restricted	444,121	398,048
PROPERTY, PLANT, AND EQUIPMENT — Net	2,106,327	2,066,286
OTHER ASSETS:		
Intangible assets — net	14,219	15,786
Investments in unconsolidated entities	69,822	72,313
Other	53,230	56,835
Total other assets	137,271	144,934
TOTAL	\$ 5,660,604	<u>\$ 5,299,842</u>

(Continued)

#### CONSOLIDATED BALANCE SHEETS AS OF DECEMBER 31, 2017 AND 2016 (In thousands)

	2017	2016
LIABILITIES AND NET ASSETS		
CURRENT LIABILITIES: Current installments of long-term debt Accounts payable Accrued salaries and wages Other accrued expenses Estimated third-party payor settlements	\$ 146,444 242,734 246,774 192,252 28,358	\$ 161,936 222,528 259,225 213,684 34,041
Total current liabilities	856,562	891,414
LONG-TERM DEBT — Less current installments	1,335,185	1,403,091
OTHER LIABILITIES: Pension and other employee benefit liabilities Self-insured liabilities Deferred gain Other	270,833 58,770 31,161 64,887	243,574 61,592 36,662 61,822
Total other liabilities	425,651	403,650
Total liabilities	2,617,398	2,698,155
NET ASSETS: Unrestricted: Controlling interest Noncontrolling interest in subsidiaries	2,862,327 115,051	2,439,653 100,119
Total unrestricted net assets	2,977,378	2,539,772
Temporarily restricted Permanently restricted	46,859 18,969	43,171 18,744
Total net assets	3,043,206	2,601,687
TOTAL	\$ 5,660,604	<u>\$ 5,299,842</u>

See accompanying notes to consolidated financial statements.

(Concluded)

### CONSOLIDATED STATEMENTS OF OPERATIONS AND CHANGES IN UNRESTRICTED NET ASSETS FOR THE YEARS ENDED DECEMBER 31, 2017 AND 2016

(In thousands)

	2017	2016
REVENUE:		
Patient service revenue (net of contractual allowances and discounts) Less provision for bad debts	\$ 5,069,034 <u>170,262</u>	\$ 4,837,262 140,151
Net patient service revenue less provision for bad debts	4,898,772	4,697,111
Other revenue	435,332	427,702
Total revenue	5,334,104	5,124,813
EXPENSES:		
Salaries, wages and fringe benefits	2,972,910	2,805,198
Professional fees	94,285	82,707
Supplies	1,018,328	987,058
Depreciation and amortization	221,591	207,842
Interest	56,446	57,687
Maintenance and service contracts	124,103	119,659
Building and equipment rental	67,115	65,850
Hospital tax assessment	96,794	97,201
Utilities	48,174	48,751
Purchased services	136,055	137,940
Other expenses	159,251	141,582
Total expenses	4,995,052	4,751,475
OPERATING INCOME	339,052	373,338
NONOPERATING INCOME:		
Investment income — net	150,878	95,603
Other nonoperating (loss) income — net	(16,033)	202
Total nonoperating income — net	134,845	95,805
EXCESS OF REVENUE OVER EXPENSES	473,897	469,143
Pension-related changes other than periodic pension cost	(508)	(49,680)
Net assets released from restriction for purchase of property and equipment	1,595	3,292
Distributions to noncontrolling interests	(37,366)	(37,277)
Other - net	(12)	(378)
INCREASE IN UNRESTRICTED NET ASSETS	<u>\$ 437,606</u>	<u>\$ 385,100</u>

See accompanying notes to consolidated financial statements.

TES
AT
Ξ
FFILIA
<b>A</b>
Z
A V
ž
E,]
AR
Ŭ
ΗĽ
AL
HE
Z
<b>RORA HEALTH CARE, INC.</b> <i>A</i>
UR
◄

# CONSOLIDATED STATEMENTS OF CHANGES IN NET ASSETS FOR THE YEARS ENDED DECEMBER 31, 2017 AND 2016

(In thousands)

	Controlling Interest Unrestricted	Noncontrolling Interest Unrestricted	Uni	Total Unrestricted	Temporarily Restricted	Permanently Restricted	Total	al
NET ASSETS — DECEMBER 31, 2015	\$ 2,066,225	\$ 88,447	÷	2,154,672	\$ 43,779	\$ 18,733	÷	2,217,184
Excess of revenue over expenses	420,194	48,949		469,143			46	469,143
Pension-related changes other than net periodic pension costs	(49,680)			(49,680)			4)	(49,680)
Contributions					10,453	11	1	10,464
Investment income					2,685			2,685
Net assets released from restrictions for operations					(10, 431)		(1	(10, 431)
Net assets released from restrictions for purchase of property and equipment	3,292			3,292	(3,292)			
Distributions to noncontrolling interest		(37,277)	_	(37,277)			(3	(37,277)
Other — net	(378)			(378)	(23)			(401)
Increase (decrease) in net assets	373,428	11,672		385,100	(608)	11	38	384,503
NET ASSETS — DECEMBER 31, 2016	2,439,653	100,119		2,539,772	43,171	18,744		2,601,687
Excess of revenue over expenses	421,599	52,298		473,897			47	473,897
Pension-related changes other than net periodic pension costs	(508)			(508)				(508)
Contributions				ļ	9,204	237		9,441
Investment income					6,756			6,756
Net assets released from restrictions for operations					(8,014)		Ŭ	(8,014)
Net assets released from restrictions for purchase of property and equipment	1,595			1,595	(1,595)			
Distributions to noncontrolling interest		(37,366)	_	(37, 366)			(3	(37,366)
Other — net	(12)			(12)	(2,663)	(12)		(2,687)
Increase in net assets	422,674	14,932		437,606	3,688	225		441,519
NET ASSETS — DECEMBER 31, 2017	\$ 2,862,327	\$ 115,051	Ś	2,977,378	\$ 46,859	\$ 18,969		3,043,206

See accompanying notes to consolidated financial statements.

#### CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED DECEMBER 31, 2017 AND 2016 (In thousands)

	2017	2016
CASH FLOWS FROM OPERATING ACTIVITIES:	ф 441 <b>-</b> 10	<b>•</b> • • • • • • • •
Change in net assets	\$ 441,519	\$ 384,503
Adjustments to reconcile change in net assets to net cash provided by operating activities:		
Pension-related changes other than net periodic pension cost	508	49,680
Realized and unrealized gains on investments, net	(123,135)	(62,374)
Loss (gain) on disposition of property, plant, and equipment	11,140	(1,511)
Loss on early extinguishment of debt	441	2,070
Impairment of long-lived assets	9,021	—
Amortization of intangible assets and other items	3,906	3,955
Amortization of deferred gains	(5,500)	(5,501)
Depreciation and amortization	221,591	207,842
Provision for bad debts	170,262	140,151
Distribution to noncontrolling interest	34,716	39,294
Increase in accounts receivable	(153,947)	(111,839)
(Decrease) increase in accounts payable and accrued expenses	(10,691)	17,972
(Decrease) increase in estimated third-party payor settlements — net	(9,604)	9,485
Increase (decrease) in pension and other employee benefit liabilities	26,751	(31,534)
Decrease in self-insured liabilities	(2,822)	(3,306)
Other changes in assets and liabilities — net	16,366	(18,382)
Net cash provided by operating activities	630,522	620,505
CASH FLOWS FROM INVESTING ACTIVITIES:		
Capital expenditures	(277,457)	(346,664)
Proceeds from sales of property, plant, and equipment	1,929	2,151
Investment in unconsolidated entities	(13,112)	(17,171)
Distributions from unconsolidated entities	6,518	6,719
Purchases of investments	(967,839)	(436,517)
Sales of investments	826,119	138,969
Net cash used in investing activities	(423,842)	(652,513)
CASH FLOWS FROM FINANCING ACTIVITIES:		
Proceeds from long-term debt and financing arrangements	58,715	218,000
Repayments of long-term debt, capital leases, and financing		
arrangements	(145,460)	(215,660)
Distribution to noncontrolling interest	(34,716)	(39,294)
Net cash used in financing activities	(121,461)	(36,954)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	85,219	(68,962)
CASH AND CASH EQUIVALENTS:		
Beginning of year	107,664	176,626
End of year	\$ 192,883	\$ 107,664
-	<u>·</u>	(Continued)

(Continued)

#### CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED DECEMBER 31, 2017 AND 2016 (In thousands)

	2017	2016
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:		
Cash paid for interest-net of capitalized interest	\$ 56,342	\$ 59,636
Cash paid for income taxes	\$ 530	\$ 1,275
SUPPLEMENTAL DISCLOSURES OF NONCASH INFORMATION:		
Capital expenditures funded through accounts payable	\$ 2,986	\$ 31,293
Capital expenditures funded through assumption of long-term debt	\$ 3,209	\$ 3,410

See notes to accompanying consolidated financial statements.

(Concluded)

#### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS AS OF AND FOR THE YEARS ENDED DECEMBER 31, 2017 AND 2016

#### 1. ORGANIZATION AND BASIS OF CONSOLIDATION

Aurora Health Care, Inc. and its affiliates (Aurora) constitute an integrated health care system providing health care services to communities throughout eastern Wisconsin, northern Illinois, and the upper peninsula of Michigan. Aurora provides a variety of health care related activities, education, philanthropic, medical research and other benefits to the communities in which they operate. Health care services include primary and specialty care, pharmacies, behavioral health care, emergency care, rehabilitation, home care, and end-of-life care.

Aurora Health Care, Inc. (the Corporation) is a Wisconsin nonstock, not-for-profit corporation. The Corporation is the parent corporation of a group of nonprofit and for profit corporations and other organizations that own and operate 14 acute-care hospital campuses, one psychiatric hospital, a network of approximately 158 physician clinic facilities, home health services, approximately 67 retail pharmacies, and other health care and related service organizations.

The accompanying consolidated financial statements include the Corporation and its wholly-owned or controlled affiliates, as disclosed in Note 18. All intercompany accounts and transactions have been eliminated in the preparation of the consolidated financial statements.

#### 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

**Use of Estimates** - The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses as of the date and period of the consolidated financial statements. Actual results could differ from those estimates.

**Cash and Cash Equivalents** - Cash and cash equivalents include highly liquid investments purchased with an original maturity or maturity at the date of purchase of three months or less, except for any cash and money market funds included in assets whose use is limited or restricted.

**Investments and Investment Income** - Investments in equity securities with readily determinable fair values and all investments in debt securities are reported at fair value based upon quoted market prices in active markets or other observable inputs and are classified as trading securities. Investments in a real estate investment trust and an international equity limited partnership are reported at net asset value (NAV) reported by the fund, which approximates fair value. Certain investments considered available to support current operations are classified as current.

Investment income or loss on funds held for professional liability coverage and certain employee benefit investments are included in other operating revenue. All other investment income or loss (including realized gains and losses, unrealized gains and losses, interest income, and dividends) is included in other nonoperating (loss) income — net, unless the income or loss is restricted by donor or law.

Assets Whose Use Is Limited or Restricted - Assets whose use is limited or restricted include investments and other assets set aside by the board of directors at their discretion for future capital improvements or for other purposes, assets held in trust under bond indenture for debt service reserve

funds, contractually restricted funds for certain defined contribution plans and assets held in reinsurance trust accounts, and donor-restricted funds.

**Patient Accounts Receivable** - Patient accounts receivable are stated at net realizable value. Patient accounts receivable are reduced by an allowance for contractual adjustments and also by an allowance for doubtful accounts. In evaluating the collectability of patient accounts receivable, Aurora analyzes its past history and identifies trends for each of its major payor sources of revenue to estimate the appropriate allowance for contractual adjustments and allowance for doubtful accounts. Management regularly reviews data about these major payor sources in evaluating the sufficiency of the allowance for contractual adjustments and allowance for doubtful accounts.

For receivables associated with services provided to patients who have third-party coverage, Aurora analyzes contractually due amounts and provides an allowance for contractual adjustments, as well as an allowance for doubtful accounts, if necessary. For receivables associated with self-pay patients, Aurora records a significant provision for bad debts and charity care in the period of service on the basis of its past experience, which indicates that many patients are unable or unwilling to pay the portion of their bill for which they are financially responsible. The difference between the standard rates (or the discounted rates, if negotiated) and the amounts actually collected after all reasonable collection efforts have been exhausted is charged off against the allowance for doubtful accounts in the period they are determined to be uncollectible.

Aurora does not maintain a material allowance for doubtful accounts for the amount due from thirdparty payors and did not have significant write-offs from third-party payors.

**Inventories** - Medical supplies, durable medical equipment held-for-sale, and other inventories are stated at the lower of cost (primarily first-in, first-out) or market. Retail pharmaceutical inventories are stated at replacement cost.

**Property, Plant, and Equipment** - Property, plant, and equipment acquisitions are recorded at cost. Donated property, plant, and equipment are recorded at fair value at the date of donation, which is then treated as cost. Costs of computer software developed or obtained for internal use, including external direct costs of materials and services and payroll and payroll-related costs for employees directly associated with internal-use software development projects, are capitalized and included in property, plant, and equipment in the accompanying consolidated balance sheets and included in capital expenditures in the accompanying consolidated statements of cash flows. Interest expense incurred during the period of construction of significant capital projects is capitalized as a component of the cost of the asset.

Property, plant, and equipment assets are depreciated on the straight-line method over the following estimated useful lives:

Buildings	40 years
Fixed equipment	10-25 years
Movable equipment	3-15 years
Computer software	3-10 years

Property, plant, and equipment capitalized under capital leases are recorded at the net present value of future minimum lease payments and are amortized on the straight-line method over the shorter of the related lease term or the estimated useful life of the asset. Amortization of property, plant, and equipment under capital leases is included in the accompanying consolidated statements of operations and changes in unrestricted net assets in depreciation and amortization expense.

Costs incurred for the use of cloud-based software for which Aurora does not own a license are expensed as incurred.

Assets Held for Sale - A long-lived asset or disposal group of assets and liabilities that is expected to be sold within one year is classified as held for sale and depreciation ceases to be recorded. For long-lived assets held for sale, an impairment charge is recorded if the carrying amount of the asset exceeds its fair value less costs to sell. Such valuations include estimates of fair values generally based upon discounted cash flows and incremental direct costs to transact a sale. As of December 31, 2017, Aurora has no properties which are being actively marketed for sale. As of December 31, 2016, assets held for sale of \$5.5 million, were recorded in the accompanying consolidated balance sheets in prepaids and other current assets.

**Pledges Receivable** - Unconditional pledges receivable are reported at fair value as contribution revenue at the date the pledge is received. Conditional pledges receivable and indications of intentions to give are reported as contribution revenue and receivables at fair value when the conditions are substantially met. Conditional pledge revenue may be net of allowances where applicable, and is reflected as an increase in temporarily restricted contributions when the conditions are substantially met, and the related receivables are reported as other current or noncurrent assets based on the estimated time of collection.

**Deferred Financing Costs and Original Issue Discounts/Premiums on Bond Indebtedness** - Longterm debt issuance costs are deferred and amortized over the term of the debt. Long-term debt issuance costs and original issue discounts/premiums on bond indebtedness are amortized using methods that approximate the effective interest rate method over the estimated average period the related bonds will be outstanding. Deferred financing costs and original issue discounts/premiums are recorded as a reduction to or increase in the related debt in the accompanying consolidated balance sheets.

**Intangible Assets** - Intangible assets are amortized on a straight-line basis over periods ranging from 1 to 15 years. Amortization of intangible assets, other than non-compete agreements, is included in other expense in the accompanying consolidated statements of operations and changes in unrestricted net assets. The amortization of non-compete agreements is included in salaries, wages and fringe benefits expense in the accompanying consolidated statements of operations and changes in unrestricted net assets.

**Asset Impairment** - Aurora periodically assesses the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset or group of assets may not be recoverable. Recoverability of an asset or group of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset, a quoted market price, or prices for similar assets. Management considers such factors as current results, trends, and future prospects, in addition to other economic factors, in determining the impairment of an asset. In 2017, \$9.0 million of impairment charges were recorded related to the impairment of construction in progress on an abandoned project, impairment of an investment in an unconsolidated entity, and impairment of a retail pharmacy prescription list intangible. See additional discussion of these impairments in Note 8 and Note 9. There were no impairment charges recorded for the year ended December 31, 2016.

Goodwill is evaluated for impairment annually at November 30, or more frequently if events or changes occur that suggest the carrying value may not be recoverable. If, after assessing events and circumstances, it is concluded that it is more likely than not that the asset is impaired, the fair value is determined and is compared to the carrying value. If the carrying value exceeds the fair value, an

impairment charge is recognized. There were no impairment charges to goodwill recorded for the years ended December 31, 2017 or 2016.

**Investments in Unconsolidated Entities** - Investments in unconsolidated entities are accounted for using the cost or equity method. Aurora applies the equity method of accounting for joint ventures and for investments with ownership interests of 50% or less, if Aurora has the ability to exercise significant influence over the operating and financial policies of the investee. All other investees are accounted for using the cost method. The income (loss) on health-related unconsolidated entities is included in other operating revenue. All other income (loss) on unconsolidated entities is included within other nonoperating (loss) income — net.

**Deferred Gain** - Aurora has entered into various sale-leaseback transactions. Certain sale-leaseback transactions resulted in deferred gains, which are amortized over the term of the lease, ranging from 10 to 25 years.

**Income Taxes** - Aurora evaluates its uncertain tax positions on an annual basis. A tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits.

Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amount of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are classified as non-current in the accompanying consolidated balance sheets.

Aurora assesses the realization of its deferred tax assets to determine whether an income tax valuation allowance is required. Based on all available evidence, both positive and negative, and the weight of that evidence to the extent such evidence can be objectively verified, Aurora determines whether it is more likely than not that all or a portion of the deferred tax assets will be realized.

**Restricted Net Assets** - Restricted net assets are used to differentiate resources, the use of which is limited by the donor or grantor, from unrestricted net assets on which the donor or grantor places no restriction or which arise as a result of the operations of Aurora. Restricted gifts and other restricted resources are recorded as additions to restricted net assets.

Restricted net assets consist of specific purpose funds, which are temporarily restricted, and endowment funds, which are permanently restricted. Temporarily restricted net assets comprise donations restricted to various specific purposes by donors and investment earnings of temporarily and permanently restricted net assets. Permanently restricted net assets are used to account for the principal amounts of gifts and bequests accepted by Aurora with donor stipulations that the principal remain intact in perpetuity and only the income from investment of the principal be expended.

When a donor restriction expires, that is, when a stipulated time restriction ends or purpose restriction is accomplished, temporarily restricted net assets are reclassified as unrestricted net assets and reported in the accompanying consolidated statements of operations and changes in unrestricted net assets as either other revenue or as net assets released from restrictions used for the purchase of property and equipment. Unrestricted contributions and donor-restricted contributions for operating purposes whose restrictions are met in the same year as received are reported as other revenue.

**Patient Service Revenue (net of contractual allowances and discounts)** - Patient service revenue is reported at the net realizable amounts from patients, third-party payors, and others for services rendered. Aurora has agreements with payors that provide for payments at amounts different from established

rates. The basis for payment under these agreements includes prospectively determined rates, per diem payments, negotiated discounts from established charges, and retroactive settlements under reimbursement agreements with third-party payors.

**Charity Care and Uninsured Care** - Aurora provides care to patients who meet certain criteria under its Helping Hands program without charge. Because Aurora does not pursue collection of amounts determined to qualify as charity care under this program, they are not reported as revenue. Aurora also provides care to uninsured patients who do not meet the criteria of the Helping Hands program at amounts less than its established rates.

**Provision for Bad Debts** - Aurora recognizes revenue on the basis of its standard rates for services provided (or on the basis of discounted rates, if negotiated or provided by policy) at the time services are rendered, prior to assessing the patient's ability to pay. As such, the entire provision for bad debts is presented as a reduction from patient service revenue. On the basis of its historical experience, a significant portion of Aurora's uninsured patients will be unwilling or unable to pay for the services provided. In addition, a portion of Aurora's insured patients will be unwilling or unable to pay the portion of their bill for which they are financially responsible. Aurora records a provision for bad debts related to uninsured patients, and insured patients for the portion of their bill for which they are financially responsible.

**Other Revenue** - Other revenue primarily comprises revenues from retail pharmacy sales, which are reported at the estimated net realizable amounts from third-party payors at the time the prescription is filled. Retail pharmacy sales were \$223.3 million and \$229.6 million for the years ended December 31, 2017 and 2016, respectively.

**Other Expenses** - Other expense primarily consists of taxes, media purchases, insurance, professional education, and banking fees.

**Other Nonoperating (Loss) Income** — **Net** - Revenues and expenses from delivering health care services and other activities that are consistent with Aurora's ongoing major or central purposes are reported in operations. Income and losses that arise from transactions that are peripheral or incidental to Aurora's main purpose, such as certain investment income; income and losses attributable to sale or disposal of property, plant, and equipment; income or loss attributable to extinguishment of debt; and equity income from non-health related joint ventures, are included in other nonoperating income (loss), net.

**Excess of Revenue over Expenses** - The performance indicator is the excess of revenue over expenses. Excess of revenue over expenses includes all changes in unrestricted net assets except for permanent transfers of assets to and from affiliates for other than goods and services, contributions of long-lived assets (including assets acquired using contributions, which by donor restriction were to be used for the purpose of acquiring such assets), distributions to noncontrolling interests, and pension-related changes other than net periodic pension costs.

**New Accounting Pronouncements** - In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, *Revenue from Contracts with Customers*, which outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry specific guidance, and requires significantly expanded disclosures about revenue recognition. The core principal of the revenue model is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The guidance may be adopted using either a full retrospective or modified retrospective approach.

Management of Aurora has evaluated the requirements of the new standard to ensure that processes, systems and internal controls are in place to collect the necessary information to implement the standard, which will be effective for Aurora as of January 1, 2018. Management of Aurora will use the modified retrospective approach to adopt this standard.

Management of Aurora utilized the portfolio practical expedient approach to analyze contracts within Aurora's core health care service lines. This practical expedient approach allows Aurora to evaluate the criteria for revenue recognition over a portfolio of similar contracts as opposed to evaluating each individual contract. Portfolios of similar characteristics must result in materially consistent revenue when compared to the revenue that would have been recognized if each patient account or contract was evaluated individually.

Management of Aurora reviewed revenue from various programs including those with variable consideration including: payments from Wisconsin's Medicaid taxation program, disproportionate share payments and settlements with third party payers. Based on this review, Management of Aurora has determined that there will not be a significant impact to revenue recognized under these programs upon the adoption of this guidance.

Management of Aurora has also considered the timing of revenue recognition under the new standard as either occurring at the time services are rendered or as services are transferred over time. Based on this review, Management of Aurora has determined that there will not be a significant impact to the timing of revenue recognition upon the adoption of this guidance.

The adoption of this ASU will result in significant changes to the presentation of financial information within the consolidated statements of operations and changes in unrestricted net assets, as well as, expanded disclosures within the notes to the consolidated financial statements. The primary change will be a change in the presentation of the provision for bad debts which relates to self-pay patients and amounts due from patients with insurance for co-pays and deductibles. Under the standard, these amounts will be a direct reduction to patient service revenue.

While the adoption of ASU 2014-09 will have a material effect on the presentation of patient service revenue in our consolidated statements of operations and changes in unrestricted net assets and on certain disclosures, this guidance will not materially impact our financial position, results of operations, or cash flows.

In February 2016, the FASB issued ASU No. 2016-02, *Leases*. This ASU introduces a lessee model that brings most leases on to the balance sheet. The standard also aligns certain of the underlying principles of the new lessor model with those in ASU No. 2014-09, the new revenue recognition standard. This standard is effective for Aurora as of January 1, 2019. Management of Aurora is currently in the process of evaluating the impact of this guidance on its consolidated financial position, results of operations and cash flows.

In August 2016, the FASB issued ASU 2016-14, *Presentation of Financial Statements of Not-for-Profit Entities*, which is intended to simplify how a not-for-profit presents net assets and other information in the financial statements. This ASU reduces the three current net asset categories to two categories. The standard also provides for enhanced disclosures on liquidity and financial performance. This ASU is effective for annual reporting periods after December 31, 2017. Aurora will adopt this standard for annual reporting as of December 31, 2018. Management of Aurora does not believe this standard will have a significant impact on its consolidated financial position, results of operations and cash flows.

In August 2016, the FASB issued ASU 2016-15, *Classification of Certain Cash Receipts and Cash Payments*, which amends guidance in Accounting Standards Codification (ASC) 230 on the

classification of certain cash receipts and payments in the statement of cash flows. The primary purpose of the ASU is to reduce the diversity of practice that has resulted from the lack of consistent principles on this topic. This standard is effective for Aurora beginning January 1, 2019. Management of Aurora anticipates that this ASU will not have a material impact on its statements of cash flows, with the primary change being the movement of certain distributions from equity method investees from cash used in investing activities to cash flows from operations.

In November 2016, the FASB issued ASU 2016-18, *Restricted Cash*, which amends guidance in ASC 230 on the presentation and activity presented within the statement of cash flows. The primary purpose of the ASU is to reduce the diversity of practice that has resulted from the lack of consistent principles on this topic. This standard is effective for Aurora beginning January 1, 2019. Management of Aurora anticipates that that this ASU will not have a material impact on its statements of cash flows, with the primary change being the inclusion of restricted cash and cash equivalents in the balances included and reconciled to within the statements of cash flows.

In March 2017, the FASB issued ASU 2017-07, *Compensation - Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost.* This ASU requires the service cost component of net periodic benefit cost related to defined benefit pension and post-retirement benefit plans to be reported in the same financial statement line as other compensation costs arising from services rendered during the period. The other components of net periodic benefit cost are required to be presented separately from service costs and outside of operating income in the statement of operations. Only the service cost component of net periodic benefit cost will be eligible for capitalization in assets. This ASU is effective for Aurora beginning January 1, 2019. Aurora will early adopt this standard as of January 1, 2018. This guidance will not have a significant impact on Aurora's consolidated statements of operations and changes in unrestricted net assets.

#### 3. COMMUNITY BENEFIT

Aurora provides health care services without charge to patients who meet the criteria of its charity care policy. The amount of charity care provided, determined on the basis of cost, is estimated based on entity-specific cost-to-charge ratios. In addition to charity care, Aurora provides services to Medicaid and other public programs, primarily Tricare, for financially needy patients, for which the payments received are less than the cost of providing services. The unpaid costs attributed to providing services under these programs are considered a community benefit. A summary of these unpaid costs are as follows for the years ended December 31, 2017 and 2016 (in thousands):

	2017	2016
Cost of charity care provided	\$ 58,298	\$ 47,477
Unpaid cost of Medicaid	332,098	335,431
Unpaid cost of other public programs	12,205	9,254
Total cost of uncompensated care	402,601	392,162
Unpaid cost of Medicare	 746,485	 645,988
Total cost of uncompensated care and unpaid cost of Medicare	\$ 1,149,086	\$ 1,038,150

In addition, Aurora is also involved in numerous other wide-ranging community benefit activities that include community health education and outreach in the form of free or low-cost clinics, health

education, health promotion and wellness programs, such as health screenings and immunizations, and various community projects, transportation services, and support groups.

#### 4. PATIENT SERVICE REVENUE AND PATIENT RECEIVABLES

Aurora has agreements with third-party payors that provide for payments to Aurora at amounts different from its established rates. A summary of the payment arrangements with major third-party payors is as follows:

- *Medicare* Inpatient acute, most hospital outpatient services, and inpatient rehabilitation services rendered to Medicare program beneficiaries are paid at prospectively determined rates. These rates vary according to patient classification systems that are based on clinical, diagnostic, and other factors. Certain inpatient nonacute and outpatient services, defined capital costs, medical education costs, select drugs, and devices related to Medicare beneficiaries are paid based on cost-reimbursement methodologies. Aurora is compensated for cost-reimbursable items at a tentative rate, with final settlement determined after submission of annual cost reports by Aurora and audits thereof by the Medicare fiscal intermediary.
- *Medicaid* Inpatient and outpatient services rendered to Medicaid program beneficiaries are reimbursed primarily based upon prospectively determined rates.
- *Other Third-Party Payors* Services rendered to patients insured by other third-party payors are reimbursed based on a discount from customary charges, prospectively determined rates per discharge, or negotiated fee schedules.

Wisconsin assesses a fee or tax on gross patient service revenue. The revenues from this assessment are used to increase payments made to hospitals for services provided to Medicaid and other medically indigent patients. Aurora's patient service revenue reflects this increase in payment for services to Medicaid and other medically indigent patients, and hospital tax assessment expense reflects the fees assessed by the State. For the years ended December 31, 2017 and 2016, patient service revenue includes \$115.3 million and \$116.2 million, respectively, related to this program, and expenses include \$96.8 million and \$97.2 million, respectively, of tax assessment fees.

The composition of patient service revenue, net of contractual allowances and discounts (before the provision for bad debts), by payor is as follows for the years ended December 31, 2017 and 2016:

	2017	2016
Managed care and all other	64%	65%
Medicare	27	26
Medicaid	8	8
Self-pay	1	1
	100%	100%

The self-pay revenue above includes only revenue from patients without insurance. The revenue related to amounts due from patients for co-insurance and deductibles is included with the primary insurance coverage.

Laws and regulations governing government and other payment programs are complex and subject to interpretation. As a result, there is a reasonable possibility that recorded estimated third-party settlements could change by a material amount. Changes in estimates relating to prior years increased patient service revenue by \$10.5 million and decreased patient service revenue by \$10.4 million for the years ended December 31, 2017 and 2016, respectively.

Aurora has filed formal appeals relating to the settlement of certain prior-year Medicare cost reports. The outcome of these appeals cannot be determined at this time.

The composition of patient accounts receivable, net of contractual allowances (before the allowance for doubtful accounts) is summarized as follows as of December 31, 2017 and 2016:

	2017	2016
Managed care and all other	50%	51%
Medicare	16	16
Medicaid	5	4
Self-pay	29	29
	100%	100%

The self-pay patient accounts receivable above includes amounts due from patients for co-insurance, deductibles, and amounts due from patients without insurance.

Aurora's allowance for doubtful accounts increased from 11.7% of gross receivable less contractual allowances for December 31, 2016 to 12.8% of gross accounts receivable less contractual allowances at December 31, 2017.

#### 5. INVESTMENTS AND ASSETS WHOSE USE IS LIMITED OR RESTRICTED

Investments and assets whose use is limited or restricted consist of the following instruments, which were measured at fair value, as of December 31, 2017 and 2016 (in thousands):

	2017	2016
Cash and cash equivalents	\$ 425,750	\$ 24,995
Fixed-income securities:		
U.S. Treasury	65,532	94,596
Corporate bonds and other debt securities	148,453	194,651
Federal agency	57,763	97,665
Fixed income mutual funds	791,695	990,518
Domestic equity securities:		
Large-cap	19,175	17,961
Mid-cap	20,472	19,257
Small-cap	23,803	22,106
Real estate	31,734	470
Equity mutual funds and exchange-traded funds	493,325	384,410
Real estate investment trust	35,174	13,953
International equity securities	150,419	142,192
International equity limited partnerships	10,871	8,497
Accrued investment income and other	 9,064	 7,104
Total	\$ 2,283,230	\$ 2,018,375
Assets whose use is limited or restricted:		
Current	\$ 5,059	\$ 5,484
Non-current	444,121	398,048
Short-term investments	 1,834,050	 1,614,843
Total	\$ 2,283,230	\$ 2,018,375

The current portion of assets whose use is limited or restricted includes the amount of assets available to meet current obligations for claims payments under the professional liability program.

Investment income for the years ended December 31, 2017 and 2016, consisted of the following (in thousands):

	2017	2016
Interest income and dividends	\$ 55,445	\$ 47,454
Net realized gains on securities	26,549	2,547
Changes in unrealized gains on investments	 96,586	 59,827
Total	\$ 178,580	\$ 109,828

Investment income for the years ended December 31, 2017 and 2016, were classified in the consolidated statements of operations and changes in unrestricted net assets and consolidated statements of changes in net assets as follows (in thousands):

	2017	2016
Other operating revenue	\$ 20,946	\$ 11,540
Investment income - net	150,878	95,603
Temporarily restricted net assets	 6,756	 2,685
Total	\$ 178,580	\$ 109,828

#### 6. FAIR VALUE

Financial instruments consist primarily of cash and cash equivalents, accounts receivable, accounts payable, accrued expenses, estimated third-party settlements, and long-term debt. Except for long-term debt, the fair values of these instruments approximate their carrying amounts, due to their short-term maturities, at December 31, 2017 and 2016. The estimated fair value of long-term debt, based on discounted cash flows at estimated current borrowing rates, was \$1,323.0 million and \$1,394.0 million at December 31, 2017 and 2016, respectively, and is categorized as Level 2 within the fair value hierarchy.

The fair values of financial assets and liabilities that are measured by the level of significant input as of December 31, 2017 and 2016 are as follows (in thousands):

Assets	December 31, 2017		Quoted Prices in Active Markets for Identical Assets (Level 1)		Other Significant Observable Inputs (Level 2)		Uno	gnificant bservable Inputs Level 3)
Recurring fair value measurements:								
Cash equivalents	\$	424,731	\$	415,554	\$	9,177	\$	
Fixed-income securities:								
U.S. Treasury		65,532		—		65,532		—
Corporate bonds and other debt securities		148,453		_		148,453		—
Federal agency		57,763		—	57,763			
Fixed income mutual funds		791,695	791,695					
Domestic equity securities:								
Large-cap		19,175		19,175	—			
Mid-cap		20,472		20,472				
Small-cap		23,803		23,803				
Real estate		31,734		31,734				
Equity mutual funds and exchange-traded funds		493,325		493,325		_		_
International equity securities		150,419		150,419				
Other		9,064		8,957				107
Total recurring fair value measurements	\$	2,236,166	\$	1,955,134	\$	280,925	\$	107
Cash		193,902						
Assets valued at net asset value		46,045						
Total cash and cash equivalents, investments and assets whose use is limited	\$	2,476,113						

Assets	De	cember 31, 2016	<b>M</b>	Quoted Prices in Active (arkets for Identical Assets (Level 1)	O	Other gnificant oservable Inputs Level 2)	Significant 10bservable Inputs (Level 3)
Recurring fair value measurements:							
Cash equivalents	\$	26,006	\$	22,037	\$	3,969	\$ 
Fixed-income securities:							
U.S. Treasury		94,596				94,596	
Corporate bonds and other debt securities		194,651				194,651	
Federal agency		97,665				97,665	
Fixed income mutual funds		990,518		990,518			
Domestic equity securities:							
Large-cap		17,961		17,961			
Mid-cap		19,257		19,257			
Small-cap		22,106		22,106			
Real estate		470		470			
Equity mutual funds and exchange-traded funds		384,410		384,410			
International equity securities		142,192		142,192			
Other		7,104		6,853			251
Total recurring fair value measurements	\$	1,996,936	\$	1,605,804	\$	390,881	\$ 251
Cash		106,653					
Assets valued at net asset value		22,450					
Total cash and cash equivalents, investments and assets whose use is limited	\$	2,126,039					
Nonrecurring fair value measurements:							
Long-lived assets held for sale		5,467		_		5,467	 
Total nonrecurring fair value measurements	\$	5,467	\$		\$	5,467	\$ 

Aurora categorizes assets and liabilities measured at fair value in the consolidated financial statements based upon whether the inputs used to determine their fair values are observable or unobservable. Observable inputs are inputs which are based on market data obtained from sources independent of the reporting entity. Unobservable inputs are inputs that reflect the reporting entity's own assumptions about pricing the asset or liability, based on the best information available under the circumstances.

The fair value of all assets and liabilities recognized or disclosed at fair value are classified based on the lowest level of significant inputs. Assets and liabilities that are measured at fair value are disclosed and classified in one of three categories. Category inputs are defined as follows:

*Level 1* — Quoted prices (unadjusted) in active markets for identical assets or liabilities on the reporting date. Investments in this level generally include exchange-traded equity securities, futures, pooled short-term investment funds, options, and exchange-traded mutual funds.

*Level 2*— Inputs other than quoted market prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. If the asset or liability has a specified (contractual) term, a Level 2 input must be observable for substantially the full term of the asset or liability. Investments in this level

generally include fixed income securities, including fixed income government obligations; asset-backed securities; certificates of deposit; derivatives; as well as certain U.S. and international equities, which are not traded on an active exchange.

Level 3 — Inputs that are unobservable for the asset or liability.

Aurora believes its valuation methods and classification in fair value levels are appropriate and consistent with other market participants based on information readily available from its service providers. Transfers between fair value levels are only done when new or additional information regarding the observability of pricing inputs is received that could result in a different classification as of the reporting date. Aurora measures the transfer between fair value levels as of the end of the reporting period, December 31. There were no significant transfers between fair value levels during the twelve months ended December 31, 2017 or 2016.

The Level 2 and 3 instruments listed in the fair value tables above utilize the following valuation techniques and inputs:

*Cash Equivalents* — Cash equivalents are comprised primarily of money market funds, which are valued based upon a net asset value of \$1.

*Fixed-Income Securities* — The fair value of fixed-income securities is primarily determined with techniques consistent with the market approach. Significant observable inputs include benchmark yields, reported trades, observable broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers, and reference data including market research publications.

Aurora holds interests in a real estate investment trust and an international equity limited partnership where the fair value of the investment held is estimated based on the net asset value of the fund. The following table summarizes the attributes relating to the nature and risk of such investments at December 31, 2017 and 2016 (dollars in thousands):

		Fair	Value			Unfu Commi					
	De	cember 31, 2017	Dec	December 31, 2016		- 31, December 31, 2017		cember 31, 2016	Redemption Frequency	Redemption Notice Period	
Real estate investment trust	\$	35,174	\$	13,953	\$	30,000	\$	_	Quarterly	90 days	
International equity limited partnership		10,871		8,497				_	Monthly	15 days	
Total	\$	46,045	\$	22,450	\$	30,000	\$				

The real estate investment trust is a core return, fully specified, open-end commingled equity real estate fund diversified by property type and location designed to provide stable, income-driven rate of return over the long term with potential for growth of net investment income and appreciation of value. The objective of the real estate investment trust is to achieve long-term aggregate annual return on invested equity of 8% to 10%, gross of fees, by investing in real estate and real estate-related investments, broadly defined, with the majority of the return being realized from income, with modest appreciation, and using leverage when appropriate.

The fair value of the real estate investment trust is determined using the calculated net asset value provided by the fund. The fair value of the underlying real estate properties held in the trust is determined giving consideration to the income, cost and sales comparison approaches of estimating property value.

The international equity limited partnership's investment objective is long-term total return. The fund pursues its investment objective primarily by investing in equity securities of non-U.S. emerging market companies. The fair value of this fund is determined using the calculated net asset value provided by the fund.

#### 7. PROPERTY, PLANT, AND EQUIPMENT

The components of property, plant, and equipment at December 31, 2017 and 2016, were summarized as follows (in thousands):

	2017	2016
Land and improvements	\$ 124,379	\$ 109,260
Buildings and fixed equipment	2,773,665	2,726,168
Movable equipment	934,434	1,107,958
Computer software	70,241	65,530
Construction-in-progress	98,033	109,973
Total property, plant, and equipment	 4,000,752	 4,118,889
Accumulated depreciation and amortization	 (1,894,425)	 (2,052,603)
Property, plant, and equipment-net	\$ 2,106,327	\$ 2,066,286

Property, plant, and equipment includes net assets under capitalized leases and other financing arrangements totaling \$129.4 million (gross of \$280.8 million, accumulated amortization of \$151.4 million) and \$140.9 million (gross of \$277.6 million, accumulated amortization of \$136.7 million) at December 31, 2017 and 2016, respectively.

Construction-in-progress at December 31, 2017 primarily consisted of costs incurred related to the expansion of Aurora BayCare's surgery center in Green Bay, Wisconsin, the expansion and renovation of the Aurora Psychiatric Hospital in Wauwatosa, Wisconsin, and design and pre-construction costs related to the replacement hospital and new outpatient surgery center and medical office building in Sheboygan, Wisconsin. Costs associated with the expansion of the Women's Center at Aurora Lakeland Medical Center in Elkhorn, Wisconsin and various other hospital and clinic renovation and expansion projects, were also included in construction-in-progress as of December 31, 2017.

Construction-in-progress at December 31, 2016 primarily consisted of costs incurred related to the expansion of Aurora BayCare Medical Center and the Vince Lombardi Cancer Clinic in Green Bay, Wisconsin, construction of a parking structure in West Allis, Wisconsin, and various other hospital and clinic renovation and expansion projects.

During the year ended December 31, 2017, Aurora completed a write-off of fully depreciated property, plant, and equipment, which had an original cost of \$317.8 million. Additionally, during the year, Aurora wrote-off assets which no longer met Aurora's capitalization policy. These assets had an original cost of \$65.0 million and resulted in a loss of \$13.4 million included in other nonoperating (loss) income — net.

#### 8. INTANGIBLE ASSETS

A summary of intangible assets and goodwill is as follows as of December 31, 2017 and 2016 (in thousands):

	2017	2016
Non-compete agreements	\$ 9,617	\$ 11,961
Prescription lists		6,632
Other	9,075	9,075
Total intangible assets	 18,692	27,668
Accumulated amortization	 (13,019)	 (20,428)
Net intangible assets	5,673	7,240
Goodwill	 8,546	 8,546
Total intangible assets-net	\$ 14,219	\$ 15,786

During 2017, Aurora sold several of its retail pharmacy locations and subsequently recorded an impairment charge of \$1.0 million related to the retail pharmacy lists. These assets were written-off in 2017, which resulted in an impairment charge of \$1.0 million.

#### 9. INVESTMENTS IN UNCONSOLIDATED ENTITIES AND NONCONTROLLING INTEREST IN SUBSIDIARIES

In April 2016, Aurora partnered with Anthem Blue Cross and Blue Shield of Wisconsin (Anthem) to form a new joint venture, Wisconsin Collaborative Insurance Company (WCIC). WCIC is a health insurance company. Aurora acquired a 50% interest in the joint venture for cash consideration of \$5.0 million and accounts for this investment under the equity method of accounting within investments in unconsolidated entities in the accompanying consolidated balance sheets. In 2017, Aurora made an additional capital contribution to WCIC of \$5.1 million. Aurora's investment in WCIC as of December 31, 2017 and 2016 was \$6.0 million and \$1.8 million, respectively.

Aurora has a 6.25% interest in StartUp Health Holdings, Inc., (StartUp Health), a global health innovation company with more than 100 digital health portfolio companies. Aurora's goal in investing in StartUp Health is to help accelerate the review and adoption of innovations aimed at transforming the delivery of care. Aurora's investment in StartUp Health is accounted for under the equity method of accounting and is presented within investments in unconsolidated entities in the accompanying consolidated balance sheets. Aurora's investment in StartUp Health was \$5.0 million as of December 31, 2016. In 2017, Aurora fully impaired its investment in Startup Health based upon a review of the company's historic performance and cash position. This impairment charge of \$5.0 million was recorded to other nonoperating (loss) income - net in the accompanying consolidated statement of operations and changes in unrestricted net assets.

Aurora has a 49% interest in Bay Area Medical Center (BAMC), a 99 bed general acute care hospital located in Marinette, Wisconsin. Aurora's investment in BAMC is accounted for under the equity method of accounting and is presented within investments in unconsolidated entities in the accompanying consolidated balance sheets. Aurora's investment in BAMC as of December 31, 2017 and

2016 was \$28.8 million and \$36.3 million, respectively. The carrying amount of Aurora's investment in BAMC is \$34.8 million and \$33.0 million less than the underlying equity in the net assets of BAMC as of December 31, 2017 and 2016, respectively. This difference represents a contingent gain which would be recognized in the event of dissolution of BAMC or if Aurora's interest in BAMC were to increase requiring BAMC to be included in the consolidated financial statements of Aurora.

Aurora has a 27% interest in Aurora Bay Area Medical Group (ABAMG), which provides inpatient, outpatient and other necessary professional medical services in Marinette, Wisconsin and its surrounding communities. BAMC owns the remaining 73% of ABAMG. Aurora's investment in ABAMG is accounted for under the equity method and is presented within investments in unconsolidated entities in the accompanying consolidated balance sheets. Aurora leases employees and buildings to ABAMG and recognized \$19.2 million and \$22.1 million of other revenue for the years ended December 31, 2017 and 2016, respectively, under the leasing agreements. Aurora made additional capital contributions to ABAMG of \$5.8 million and \$6.0 million for the years ended December 31, 2017 and 2016, respectively. Aurora's investment in ABAMG was \$0.5 million and \$0.8 million as of December 31, 2017 and 2017 and 2016, respectively.

Aurora has a 50% investment in the Menomonee Falls Ambulatory Surgery Center, LLC, and a 20% investment in Froedtert Surgery Center, LLC (collectively, the Surgery Centers). The Surgery Centers provide various types of outpatient surgical procedures. Aurora's investment in the Surgery Centers of \$5.8 million and \$5.7 million as of December 31, 2017 and 2016, respectively, is accounted for under the equity method of accounting and is presented within investments in unconsolidated entities in the accompanying consolidated balance sheets. The carrying amount of Aurora's investment in the Surgery Centers is different from the underlying equity in the net assets of the investees due to goodwill recorded upon the initial investment in the Surgery Centers. The Surgery Centers were sold in February 2018 as disclosed in Note 20.

				2017		
	Bay Area					
	Medical			Surgery	Other	
	Center <sup>(1)</sup>		ABAMG	Centers	Investees	Total
Total assets	\$ 233,180	\$	6,150 \$	13,754 \$	37,032 \$	290,116
Total liabilities	105,407		4,169	1,804	24,581	135,961
Equity	127,773		1,981	11,950	12,451	154,155
Total revenue	96,759		24,032	13,611	180,248	314,650
Net income (loss)	3,598		(22,251)	1,020	4,568	(13,065)
				2016		
	Bay Area					
	Medical			Surgery	Other	
	Center <sup>(1)</sup>		ABAMG	Centers	Investees	Total
Total assets	\$ 198,957	\$	6,896 \$	13,109 \$	28,800 \$	247,762
Total liabilities	60,441		4,004	2,143	62,461	129,049
Equity	138,516		2,892	10,966	(33,661)	118,713
Total revenue	86,666		30,958	15,682	73,174	206,480
Net (loss) income	(3,902)	)	(21,928)	1,764	5,978	(18,088)

The summarized financial position and results of operations for the entities accounted for under the equity method as of and for the year ended December 31, 2017 and 2016, is as follows (in thousands):

<sup>(1)</sup>ABAMG is included in the consolidated financial results of Bay Area Medical Center.

Aurora Medical Group has a majority interest in BayCare Aurora, LLC (Aurora BayCare), a Wisconsin limited liability company established for the purpose of owning and operating a hospital and other medical care facilities in Green Bay, Wisconsin. Under certain circumstances, the operating agreements of Aurora BayCare may require additional contributions from the members and permit distributions of their equity. Aurora BayCare is included in the accompanying consolidated financial statements. At December 31, 2017 and 2016, the noncontrolling interest in Aurora BayCare totaled \$110.5 million and \$96.0 million, respectively, and was included in noncontrolling interest in subsidiaries' unrestricted net assets. During 2017 and 2016, distributions totaling \$31.8 million and \$32.5 million, respectively, were made to the minority shareholders.

Aurora has a controlling financial interest in three surgery centers. The financial position and results of operations of the surgery centers are included in the consolidated financial statements. At December 31, 2017 and 2016, the noncontrolling interest in the surgery centers totaled \$4.6 million and \$4.1 million, respectively, and was included in noncontrolling interest in subsidiaries' unrestricted net assets. During 2017 and 2016, distributions totaling \$5.5 million and \$4.8 million, respectively, were made to the minority shareholders.

#### **10. INCOME TAXES**

The Corporation and certain of its affiliates are not-for-profit corporations as described in Section 501(c)(3) of the Internal Revenue Code (the Code) and have been recognized as tax exempt on related income pursuant to Section 501(a) of the Code.

Aurora Health Care Ventures, Inc. (Ventures) and its subsidiaries are taxable entities. Ventures is a subsidiary of the Corporation.

Aurora BayCare is treated as a partnership for income tax purposes. Income and losses of Aurora BayCare are passed through to its members. Aurora BayCare income passed through to Aurora is not considered taxable income to Aurora unless it is considered unrelated business income.

Aurora Liability Assurance, Ltd. has elected to be treated as a disregarded entity for income tax purposes.

The provision for income taxes for the years ended December 31, 2017 and 2016, consists of the following (in thousands):

	2017	2016
Current tax expense:		
Federal	\$ 3,022	\$ 2,228
State	7	332
Deferred tax expense	2,790	626
Total tax expense	\$ 5,819	\$ 3,186

Income tax expense is included within other operating expenses in the accompanying consolidated statements of operations and changes in unrestricted net assets.

In December 2017, the President signed into law the Tax Cuts and Jobs Act (the "Tax Act"). The Tax Act reduced the corporate federal tax rate from 35% to 21%, which resulted in a decrease in our net deferred tax asset and a corresponding increase in tax expense.

	2017					2016
	Assets		Liabilities			Assets
Depreciation and fixed-asset differences	\$		\$	(240)	\$	237
Receivables (doubtful accounts and adjustments)		12		_		260
Accruals for retained insurance risks						342
Investments and other assets		1,284				1,176
Other accrued liabilities		310				799
Benefit plans		3,712				6,222
Net operating loss carryforwards		1,562				2,174
Subtotal deferred tax assets		6,880		(240)		11,210
Valuation allowance		(648)				(1,080)
Total deferred income taxes	\$	6,232	\$	(240)	\$	10,130

The following table discloses those significant components of deferred tax assets, including any valuation allowance, at December 31, 2017 and 2016 (in thousands):

The valuation allowance of \$0.6 million and \$1.1 million as of December 31, 2017 and 2016, respectively, are primarily attributable to certain federal and state net operating loss carryovers that, more likely than not, will expire unutilized.

At December 31, 2017, federal net operating loss carryforwards totaled \$5.3 million, which expire from 2018 to 2037. At December 31, 2017, state operating loss carryforwards totaled \$8.8 million, which expire from 2024 to 2037.

There have been no uncertain tax positions recorded in 2017 or 2016.

#### 11. LONG-TERM DEBT

Long-term debt at December 31, 2017 and 2016, is summarized as follows (in thousands):

		2017		2016
Wisconsin Health and Educational Facilities Authority (WHEFA)				
fixed-rate bonds:				
Series 2009A (5.15% weighted average coupon for 2017 and 5.12% for 2016)		22,500		22,750
Series 2009B (1.25% weighted average coupon for 2017 and 3.22% for 2016)		—		65,000
Series 2010A (5.45% weighted average coupon for 2017 and 5.43% for 2016)		157,750		162,375
Series 2010B (5.00% weighted average coupon for 2017 and 2016)		41,620		61,895
Series 2012A (4.77% weighted average coupon for 2017 and 2016)		203,885		208,120
Series 2013A (5.19% weighted average coupon for 2017 and 2016)		115,750		115,750
Total fixed-rate bonds		541,505	·	635,890
WHEFA variable-rate bonds:				
Series 1999C (0.85% effective rate for 2017 and 0.43% for 2016)	\$	50,000	\$	50,000
Series 2008A (0.97% effective rate for 2017 and 0.49% for 2016)		80,000		80,000
Series 2008B (0.91% effective rate for 2017 and 0.43% for 2016)		79,470		79,470
Series 2010C (0.94% effective rate for 2017 and 0.36% for 2016)		102,465		102,690
Series 2012B (0.79% effective rate for 2017 and 0.36% for 2016)		36,000		37,700
Series 2012C (0.79% effective rate for 2017 and 0.36% for 2016)		36,000		37,700
Series 2012D (0.83% effective rate for 2017 and 0.41% for 2016)		53,115		55,930
Total variable-rate bonds		437,050		443,490
Unamortized original issue, premium, net		10,016		11,786
Total WHEFA debt		988,571	· <u> </u>	1,091,166
Taxable bonds:				
Series 2015A (1.48% effective rate for 2017 and 0.88% for 2016)		40,000		40,000
Series 2016A (1.97% effective rate for 2017 and 2016)		112,250		125,000
Series 2016B (1.99% effective rate for 2017 and 2016)		83,510		93,000
Total taxable bonds		235,760	· <u> </u>	258,000
Total taxable bolids		255,700		238,000
Capital lease obligations and financing arrangements		202,205		220,829
Line of credit (1.87% effective rate for 2017)		58,500		—
Notes payable		5,595		5,943
Deferred financing costs — net		(9,002)		(10,911)
Total long-term debt		1,481,629		1,565,027
Less amounts classified as current:				
Current installments		(146,444)		(144,480)
Long-term debt classified as current due to contractual requirements				(17,456)
Total amounts classified as current		(146,444)		(161,936)
Long-term debt — net of current portion	\$	1,335,185	\$	1,403,091
-	_		_	

Pursuant to loan agreements with WHEFA, Aurora system entities have borrowed the proceeds of the revenue bonds listed above from WHEFA (WHEFA Bonds). Aurora's obligation to repay WHEFA is secured by Obligations issued under a Master Trust Indenture (the Aurora Indenture). All outstanding

debt under the Aurora Indenture represents joint and several obligations of the members of the Obligated Group and are secured by a pledge of unrestricted receivables and a mortgage on Aurora St. Luke's Medical Center. Of the total fixed-rate WHEFA bonds, \$47.4 million is collateralized by bond insurance. Additionally, certain of the WHEFA variable-rate bonds are secured by letters of credit, as described below.

The variable-rate demand bonds (VRDBs) are collateralized by \$454.1 million of irrevocable direct-pay letters of credit issued by commercial banks. Under certain circumstances, the VRDBs are subject to mandatory purchase by Aurora. The letters of credit provide interim financing to Aurora in the event Aurora is unable to remarket tendered bonds. The letters of credit expire at various dates through 2021 and have various repayment terms. For \$327.1 million of the letters of credit, principal payments are due quarterly, beginning the earlier of one year from the date of the advance or two months after the expiration date of the letter of credit's stated expiration date. For the remaining \$127.0 million letters of credit, principal payments are due quarterly, beginning the earlier of the letter of credit and shall amortize over a three-year period, not to exceed three years from the letter of credit's stated expiration date. For the remaining \$127.0 million letters of credit, principal payments are due quarterly, beginning the earlier of one year from the date of the advance or two months after the expiration date of the letter of credit's stated expiration date. For the remaining \$127.0 million letters of credit, principal payments are due quarterly, beginning the earlier of one year from the date of the advance or two months after the expiration date of the letter of credit and shall amortize over a two-year period, not to exceed two years from the letter of credit's stated expiration date. At December 31, 2017 and 2016, no draws were outstanding under the letters of credit. Aurora's repayment obligations to the commercial banks that provide the letters of credit are secured by Obligations issued under the Aurora Indenture.

On August 15, 2016, Aurora issued \$218.0 million of Series 2016A and 2016B fixed rate taxable bonds which were directly placed with two commercial banks. The proceeds of the 2016A and 2016B Bonds were used to redeem \$81.2 million of the Series 1993 Fixed Rate Revenue Bonds, \$67.5 million of the Series 2009B-2 Fixed Rate Revenue Bonds and pay off the balance on the Term Note of \$9.8 million. The remaining proceeds were used primarily to fund various capital projects. Aurora had a fixed-to-variable interest rate swap which was terminated in connection with this transaction. The financing resulted in a loss on early extinguishment of debt of \$2.0 million, included in nonoperating income (loss), net, in the accompanying consolidated statement of operations and changes in unrestricted net assets. Aurora's repayment obligations for Taxable Bonds are secured by Obligations issued under the Aurora Indenture.

Aurora has three series of taxable bonds outstanding, which were issued directly by Aurora and placed with multiple commercial banks (the Taxable Bonds). The outstanding principal amount of the Taxable Bonds is \$235.8 million and \$258.0 million at December 31, 2017 and 2016, respectively. The Series 2015A Taxable Bonds are subject to a mandatory tender on April 15, 2021.

At December 31, 2017 and 2016, Aurora is obligated under capital lease and financing arrangements entered into in connection with certain leasing and sale-leaseback transactions. These arrangements, which relate to various administrative and medical support buildings, had initial lease terms of 15 to 25 years. In certain cases, the lease terms for these arrangements include renewal options, purchase options, expansion rights, and rent escalation clauses. The buyer-lessors for such transactions are unrelated special purpose entities. Aurora has excluded the unrelated special purpose entities' assets, liabilities, results of operations, and cash flows from its consolidated financial statements because the residual risks and rewards of the leased assets, as well as the obligations imposed by the underlying debt, reside with the lessors, not Aurora. In January 2018, Aurora purchased certain properties which were previously leased as disclosed in Note 20.

In August 2017, Aurora entered into a \$250.0 million line of credit with a syndicate of commercial banks. The credit facility bears interest at a base rate plus margin based on Aurora's current bond ratings. Proceeds of a \$58.5 million draw in August 2017 and \$6.5 million of debt reserve funds were used to refund a mandatory tender of \$65.0 million on the 2009B bonds. The \$58.5 million draw remains

outstanding as of December 31, 2017. Aurora's repayment obligations under the credit agreement are secured by Obligations issued under the Aurora Indenture.

At December 31, 2017 and 2016, Aurora had a \$60.0 million line of credit with a commercial bank, bearing interest at either the commercial bank floating rate or LIBOR plus 0.50%, based upon the option of Aurora. As of December 31, 2017 and 2016, three letters of credit issued under the line of credit totaling \$40.5 million and \$38.8 million, respectively, were outstanding. There were no outstanding draws on the line of credit or letters of credit as of December 31, 2017 or 2016. Aurora's repayment obligations under the line of credit are secured by Obligations issued under the Aurora Indenture.

Scheduled maturities on long-term debt (excluding amortization of remaining net unamortized original issue premiums of \$10.0 million and deferred financing costs of \$9.0 million), capital lease obligations, and financing arrangements, and related sublease rental income, at December 31, 2017, were as follows (in thousands):

	L	ong-Term Debt	Ot and	bital Lease bligations Financing angements	Sublease Rental Income
2018	\$	123,479	\$	35,254	\$ 5,176
2019		67,365		37,166	1,709
2020		70,010		37,098	1,582
2021		72,309		35,155	564
2022		74,611		43,482	256
Thereafter		870,636		74,887	 138
Total long-term debt	\$	1,278,410			
Total minimum lease payments and sublea	ise re	ntal income		263,042	\$ 9,425
Less amount representing interest				(60,837)	
Net present value of minimum lease paymen	ts				
for capital lease obligations and financing art	range	ements	\$	202,205	

Certain borrowing agreements require sinking fund deposits with a trustee sufficient to pay principal and interest when due. Further, certain of the borrowing agreements contain various covenants regarding maintenance of property, continuation of operations, issuance of additional debt, and maintenance of certain financial ratios and indicators. Aurora was in compliance with all of its financial covenants as of December 31, 2017.

#### **12. EMPLOYEES' BENEFIT PLANS**

Aurora has a defined benefit pension plan (the Pension Plan) covering substantially all of its employees hired before January 1, 2013, with at least 1,000 hours of work in a calendar year. The Pension Plan was frozen on December 31, 2012. Benefits are based on years of service and the employees' final average earnings, as defined. Aurora funds the Pension Plan based on the amount calculated by the Pension Plan's actuaries to meet the minimum Employee Retirement Income Security Act (ERISA) funding requirements. The Pension Plan assets and obligations are measured at December 31. Employer contributions were \$50.0 million during the year ended December 31, 2016. There were no employer

contributions made to the plan during the year ended December 31, 2017. The actuarial cost method used to compute Pension Plan liabilities and expenses is the projected unit credit method.

A summary of the changes in the projected benefit obligation, fair value of plan assets and funded status of the Pension Plan as of December 31, 2017 and 2016, is as follows (in thousands):

	2017	2016
Accumulated benefit obligation	\$ 1,623,512	\$ 1,473,113
Change in projected benefit obligation:		
Projected benefit obligation at beginning of measurement period	\$ 1,473,113	\$ 1,367,641
Interest cost	64,187	63,291
Plan amendments		111
Net actuarial loss	138,055	88,151
Benefits paid	 (51,843)	 (46,081)
Projected benefit obligation at end of year	 1,623,512	 1,473,113
Change in plan assets:		
Fair value of plan assets at beginning of measurement period	1,356,085	1,249,653
Actual income on plan assets	203,229	102,513
Employer contributions		50,000
Benefits paid	 (51,843)	 (46,081)
Fair value of plan assets at end of year	 1,507,471	 1,356,085
Unfunded status at end of year	\$ (116,041)	\$ (117,028)
Net periodic pension income is composed of the following:		
Interest cost on projected benefit obligation	\$ 64,187	\$ 63,291
Expected return on plan assets	(74,092)	(70,098)
Net amortization and deferral	 8,410	 6,166
Net periodic pension income	\$ (1,495)	\$ (641)

The unfunded status of the Pension Plan is recorded in the accompanying consolidated balance sheets in non-current pension and other employee benefit liabilities.

The net actuarial loss not yet recognized as a component of net periodic pension cost was \$444.3 million and \$443.7 million as of December 31, 2017 and 2016, respectively and is included in unrestricted net assets in the accompanying consolidated balance sheets.

The net actuarial gain or loss recognized as a component of pension-related changes other than net periodic pension cost was a loss of \$0.5 million and \$49.7 million for the years ended December 31, 2017 and 2016, respectively. The expected amortization amount to be included in the net periodic pension cost in 2018 is a net actuarial loss of \$11.6 million.

Assumptions used to determine the benefit obligation at the measurement date and the net periodic pension cost as of December 31, 2017 and 2016, were as follows:

	2017	2016
Discount rate-pension expense	4.42%	4.70%
Discount rate-projected benefit obligation	3.79	4.42
Expected long-term rate of return on assets-pension expense	5.50	5.50

The discount rate used by Aurora is based on a hypothetical portfolio of high-quality bonds with cash flows matching the Pension Plan's expected benefit payments.

The expected long-term rate of return is based on the asset allocation of the total portfolio considering capital return assumptions from various sources. Aurora's investment objective is to achieve its targeted long-term rate of return while avoiding excessive risk. Risk is effectively managed through diversifying the asset allocation across a broad spectrum of assets including domestic and international equities and fixed income securities with varying correlations to movements in interest rates along the yield curve. These investments are readily marketable and can be sold to fund benefit payment obligations as they become payable. Overall funded status risk of the Pension Plan is managed by matching the duration of plan assets to plan liabilities to mitigate the impact of changes in interest rates on funded status.

The fair market value of the Pension Plan assets at December 31, 2017 and 2016, is as follows (in thousands):

	De	December 31, 2017		Prices in Active		in Active Markets for Identical Assets		Significant Other Observable Inputs (Level 2)		ignificant observable Inputs
Cash and cash equivalents	\$	49,424			\$ 49,424		\$	(Level 3)		
Fixed-income securities:	Ψ	19,121	Ψ		Ψ	19,121	Ψ			
U.S. Treasury		172,266				172,266				
Corporate bonds and other debt		1, _,_ 00				1,2,200				
securities		646,051		—		646,051				
Federal agency		880		—		880				
Fixed-income mutual funds		56,993		56,993		—				
Domestic equity securities:										
Large-cap		56,033		56,033		—				
Mid-cap		34,402		34,402		—				
Small-cap		63,656		63,656		—				
Real estate		8,451		8,451		_				
Equity mutual funds and exchange traded funds		147,893		147,893						
International equity securities		144,628		144,628						
Total recurring fair value measurements		1,380,677	\$	512,056	\$	868,621	\$			
Assets valued at net asset value		128,426								
Total Pension Plan Assets	\$	1,509,103								

	De	cember 31, 2016	i Ma I	Quoted Prices n Active arkets for dentical Assets Level 1)	Ol	gnificant Other oservable Inputs Level 2)	Un	ignificant observable Inputs (Level 3)
Cash and cash equivalents	\$	28,838	\$		\$	28,838	\$	_
Fixed-income securities:								
U.S. Treasury		139,500		—		139,500		_
Corporate bonds and other debt securities		596,518				596,518		_
Federal agency		1,434		—		1,434		_
Fixed-income mutual funds		53,520		53,520				_
Domestic equity securities:								
Large-cap		51,224		51,224				_
Mid-cap		31,184		31,184				_
Small-cap		63,972		63,972		_		
Real estate		8,833		8,833		_		
Equity mutual funds and exchange traded funds		137,349		137,349				
International equity securities		127,374		127,374				
Total recurring fair value measurements		1,239,746	\$	473,456	\$	766,290	\$	
Assets valued at net asset value		117,704			_			
Total Pension Plan Assets	\$	1,357,450						

There were no significant transfers between fair value levels during 2017 or 2016.

The Pension Plan holds shares or interests in investment funds where the fair value of the investment held is estimated based on the net asset value of the investment funds. The following table summarizes the attributes relating to the nature and risk of these investments at December 31, 2017 and 2016 (in thousands):

		Fair	Fair Value Unfunded Commitments							
	Dec	ember 31, 2017	Dee	cember 31, 2016	Dec	cember 31, 2017	Dee	cember 31, 2016	Redemption Frequency	Redemption Notice Period
Real estate investment trust	\$	37,167	\$	34,176	\$	5,000	\$	_	Quarterly	90 Days
Commingled funds		41,133		44,351					Daily	0 Days
International equity limited partnership		50,126		39,177				_	Monthly	15 Days
Total	\$	128,426	\$	117,704	\$	5,000	\$			

The real estate investment trust is a core return, fully specified, open-end commingled equity real estate fund diversified by property type and location designed to provide stable, income-driven rate of return over the long term with potential for growth of net investment income and appreciation of value. The objective of the real estate investment trust is to achieve long term aggregate annual return on invested equity of 8% to 10%, gross of fees, by investing in real estate and real estate-related investments,

broadly defined, with the majority of the return being realized from income, with modest appreciation, and using leverage when appropriate.

The commingled funds include investments held with two separate funds. The objectives of one of the commingled funds is to maximize total return and outperform the Barclays U.S. Long Government/ Credit index, gross of fees, over a market cycle, while maintaining total return risk similar to that of the benchmark. This fund primarily invests in corporate bonds, U.S. Treasury obligations and other U.S. government and agency securities, debt securities of foreign governments and supranational organizations, municipal obligations, and asset-backed, mortgage related and mortgage backed securities. The objectives of the other commingled fund is to maximize the total return and outperform the Barclays Long Credit Index, while maintaining total return risk similar to that of the benchmark over a market cycle. This fund invests primarily in investment grade fixed income securities.

The international equity limited partnership's investment objective is long-term total return. The fund pursues its investment objective primarily by investing in equity securities of non-U.S. emerging market companies. The fair value of this fund is determined using the calculated net asset value provided by the fund.

A reconciliation of the fair value of Pension Plan assets, as presented above, to the fair value of plan assets utilized in determining the unfunded status of the Pension Plan as of December 31, 2017 and 2016, is as follows (in thousands):

	2017	2016
Fair value of plan assets Payable for pending trades-net	\$ 1,509,103 (1,632)	\$ 1,357,450 (1,365)
Fair value of plan assets at end of measurement period	\$ 1,507,471	\$ 1,356,085

The asset allocation of Aurora's Pension Plan assets at December 31, 2017 and 2016, is as follows:

	20	17	20	16	
	Strategic		Strategic		
	Target	Actual	Target	Actual	
Equity securities	33%	33%	33%	33%	
Fixed-income securities	64	61	64	62	
Real estate	3	3	3	3	
Cash and cash equivalents		3		2	
Total	100%	100%	100%	100%	

Aurora expects to make the following contributions to and estimated benefit payments from its Pension Plan (in thousands):

Expected contributions in 2018	\$ 22,200
Estimated han offit normanter	
Estimated benefit payments:	
2018	\$ 61,631
2019	66,238
2020	70,176
2021	73,637
2022	76,541
2023 through 2026	 418,741
Total	\$ 766,964

Aurora and certain affiliates sponsor defined contribution and retirement savings plans (the Defined Contribution Plans), whereby Aurora contributes a percentage of participants' qualifying compensation up to certain limits as outlined in the Defined Contribution Plans or other amounts as designated by the affiliates' board of directors. Included in salaries, wages and fringe benefits expense in the accompanying consolidated statements of operations and changes in unrestricted net assets for the years ended December 31, 2017 and 2016, is \$152.1 million and \$144.9 million, respectively, for contributions to the Defined Contribution Plans.

Aurora also sponsors a noncontributory Section 457(b) defined contribution plan (the 457(b) Plan) covering select employees, where participants may contribute a percentage of qualifying compensation up to certain limits as defined by the 457(b) Plan. The 457(b) Plan assets and liabilities, each totaling \$130.6 million and \$102.6 million at December 31, 2017 and 2016, respectively, are included in long-term assets whose use is limited or restricted and pension and other employee benefit liabilities, in the accompanying consolidated balance sheets. The assets of this 457(b) Plan are subject to the claims of the general creditors of Aurora. Net investment income from the 457(b) Plan was \$17.8 million and \$8.7 million for the years ended December 31, 2017 and 2016, respectively. Net investment income (loss) from the 457(b) Plan is included in other operating revenue with an equal offsetting expense in salaries, wages and fringe benefits in the accompanying consolidated statements of operations and changes in unrestricted net assets.

#### 13. SELF-FUNDED HEALTH, DENTAL, AND OTHER BENEFITS

Aurora sponsors self-funded health and dental insurance plans covering substantially all of their employees and their dependents. Health and dental insurance expense under the plans is based upon actual claims paid, administration fees, and provisions for unpaid and unreported claims at year-end. At December 31, 2017 and 2016, the estimated liability for unpaid and unreported claims of \$9.4 million and \$10.6 million, respectively, was included in accrued liabilities. Costs of Aurora's self-funded health and dental insurance program of \$28.2 million and \$31.7 million for the years ended December 31, 2017 and 2016, respectively, for services provided by non-affiliated providers were included in salaries, wages and fringe benefits expense.

Aurora also provides salary continuation payments to current and inactive employees who are eligible to receive long-term disability and workers' compensation, under self-funded arrangements. Aurora measures the cost of its unfunded obligations under such programs based upon actuarial calculations and records a liability on a discounted basis. At December 31, 2017 and 2016, Aurora had accrued estimated

benefit obligations of \$9.0 million and \$9.2 million, respectively, included in accrued liabilities, and \$27.9 million and \$27.4 million, respectively, included in self-insured liabilities.

#### 14. TEMPORARILY AND PERMANENTLY RESTRICTED NET ASSETS

Temporarily and permanently restricted net assets were available for the following purposes at December 31, 2017 and 2016 (in thousands):

	<b>Temporarily Restricted</b>				<b>Permanently Restricted</b>			
		2017		2016		2017		2016
Health education	\$	6,601	\$	7,467	\$	10,316	\$	10,082
Specific program services		29,525		24,494		6,933		6,941
Research		8,038		9,115		1,506		1,507
Purchase of building and equipment		1,779		1,209				_
Indigent care		916		886		214		214
Total restricted net assets	\$	46,859	\$	43,171	\$	18,969	\$	18,744

At December 31, 2017 and 2016, permanently restricted net assets represent the principal amount of gifts that are to be held in perpetuity. Investment income on the related assets is expendable to support health care and other services and is reported as temporarily restricted investment income.

Aurora's endowment consists of 49 individual funds, including donor-restricted endowment funds. Net assets associated with endowment funds are classified and reported based on the existence or absence of donor-imposed restrictions.

The Foundation Board has interpreted the Uniform Prudent Management of Institutional Funds Act (UPMIFA) as requiring the preservation of the fair value of the original gift as of the gift date of the donor-restricted endowment funds absent explicit stipulations to the contrary. As a result of this interpretation, Aurora classifies as permanently restricted net assets (a) the original value of gifts donated to the permanent endowment, (b) the original value of subsequent gifts to the permanent endowment, and (c) accumulation to the permanent endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund. The remaining portion of the donor-restricted endowment fund that is not classified in permanently restricted net assets is classified as temporarily restricted net assets until those amounts are appropriated for expenditure by Aurora. Aurora considers the following factors in making a determination to appropriate or accumulate donor-restricted endowment funds: (1) the duration and preservation of the fund, (2) the purposes of the organization and the donor-restricted endowment fund, (3) general economic conditions, (4) the possible effect of inflation and deflation, (5) the expected total return from income and the appreciation of investments, (6) other resources of Aurora, and (7) the investment policies of Aurora.

Aurora has adopted investment and spending policies for endowment assets that attempt to provide a predictable stream of funding to programs supported by its endowment, while seeking to maintain the purchasing power of the endowment assets. Aurora's investment objective is to achieve its targeted long-term rate of return while avoiding excessive risk. Risk is effectively managed through diversification, which is achieved by employing various investment managers and mutual funds to direct investments over a broad spectrum of assets, including equities and fixed-income securities.

Aurora has a spending policy that at least 5% of the funds available for expenditure held by the Foundation at the beginning of the fiscal year will be expended on an annual basis. The amount available

for expenditure would exclude the corpus of permanently restricted and term donor-restricted endowment funds.

From time to time, the fair value of assets associated with individual donor-restricted endowment funds may fall below the level that the donor requires Aurora to retain as a fund of perpetual duration. There were no such deficiencies as of December 31, 2017 and 2016.

Information regarding the composition of the endowment investments and activity as of and for the years ended December 31, 2017 and 2016, is as follows (in thousands):

	Т	Donor- Restricted emporarily Restricted	Р	ermanently Restricted	Total
Endowment net assets-December 31, 2015	\$	10,235	\$	18,733	\$ 28,968
Investment return:					
Investment income		736			736
Net change in unrealized gains		53			 53
Total investment return		789		—	789
Contributions		10		11	21
Appropriation of endowment assets for					
expenditure		(1,825)		—	 (1,825)
Endowment net assets-December 31, 2016		9,209		18,744	27,953
Investment return:					
Investment income		1,470			1,470
Net change in unrealized gains		310			 310
Total investment return		1,780			1,780
Contributions				237	237
Appropriation of endowment assets for					
expenditure		(1,615)			(1,615)
Other changes-transfers between funds		12		(12)	 
Endowment net assets-December 31, 2017	\$	9,386	\$	18,969	\$ 28,355

#### **15. FUNCTIONAL EXPENSES**

Aurora provides health care services to residents within its geographic areas. Expenses related to providing these services for the years ended December 31, 2017 and 2016, are as follows (in thousands):

	2017	2016
Health care services General and administrative	\$ 4,212,503 782,549	\$ 4,006,594 744,881
Total	\$ 4,995,052	\$ 4,751,475

General and administrative expenses primarily include information technology, legal, finance, purchasing, patient billing, and human resources.

#### 16. COMMITMENTS AND CONTINGENCIES

**Operating Lease Agreements** - Aurora has various noncancelable operating lease agreements, primarily for medical support buildings and equipment, which have remaining fixed terms ranging from one to 20 years at December 31, 2017. Some leases contain renewal options, fair value purchase options, and escalation clauses. Aurora subleases certain of its medical support buildings.

Net future minimum lease payments under non-cancelable operating leases with initial or remaining lease terms in excess of one year at December 31, 2017, are as follows (in thousands):

	Leas	Lease Payments		Sublease Income		Net Future Minimum Lease Payments	
2018	\$	55,389	\$	(686)	\$	54,703	
2019		53,989		(250)		53,739	
2020		51,097		(212)		50,885	
2021		48,554		(76)		48,478	
2022		41,507		(78)		41,429	
Thereafter		93,055				93,055	
Total	\$	343,591	\$	(1,302)	\$	342,289	

Aurora West Allis Medical Center has the right to operate the hospital under the terms of a lease agreement with the City of West Allis (the City). In accordance with the lease agreement, the City has title to all assets and any subsequent additions (with the exception of certain equipment used by Aurora for laboratory services). Aurora West Allis Medical Center has exclusive right to the use of the assets and the obligation to maintain and replace them. The historical cost to Aurora of the leased facilities is included within Aurora's property, plant, and equipment. The agreement provides for annual payments of less than \$0.1 million in lieu of annual lease payments, and includes payment escalations each subsequent year. The lease expires in 2063.

**Litigation** - Aurora is subject to various regulatory investigations, legal proceedings, and claims which are incidental to its normal business activities.

Aurora believes it has made adequate provision for potential exposures relating to its legal matters. In the opinion of management, the amount of ultimate liability with respect to these actions will not materially affect the consolidated results of operations or net assets of Aurora.

**Vendor Arrangements** - Aurora routinely enters into long-term arrangements covering volume purchases of medical supplies and equipment. Certain of the agreements, which are generally cancelable without penalty, require Aurora to meet targeted levels of expenditures in order to maintain favorable pricing terms.

**Insurance Coverage** - Aurora is commercially insured for workers' compensation stop-loss, auto, property, boiler and machinery, umbrella/excess liability, directors' and officers' liability, and other customary business liabilities.

#### 17. GENERAL AND PROFESSIONAL LIABILITY INSURANCE

Commercial insurance companies have issued policies covering Aurora's primary professional, general and managed care errors and omission liability risks. Aurora's professional and general liability insurance is on an occurrence basis, while managed care errors and omissions liability risks are written on a claims-made basis.

Aurora's hospitals, clinics, surgery centers, physicians, and certified registered nurse anesthetist providers that provide health care in Wisconsin are qualified health care providers as defined by Wisconsin state statute, and have separate professional liability limits of \$1.0 million per claim and \$3.0 million annual aggregate applied to each qualified provider. Losses in excess of these amounts are fully covered through mandatory participation in the State of Wisconsin Injured Patients and Families Compensation Fund (the Fund).

Aurora also has professional liability coverage for its providers and affiliates that do not qualify for the Fund coverage, as well as general liability for all of its entities. These coverages provide a number of shared professional liability limits and shared general liability limits totaling \$2.0 million per occurrence and \$4.0 million annual aggregate for most providers. Losses in excess of these amounts are covered by Aurora's umbrella/excess insurance.

The professional, general and managed care liabilities discussed above have been ceded back to Aurora Liability Assurance, Ltd. (ALA), a wholly-owned subsidiary of Aurora, through reinsurance agreements. Independent actuaries evaluate the required provision for outstanding losses related to these risks. At December 31, 2017 and 2016, Aurora has recorded a liability for outstanding losses, including incurred but not reported, discounted at 4.0% totaling \$32.0 million and \$35.2 million, respectively. Of this amount, a portion of the liability for outstanding losses was included in accrued expenses and a portion was included in self-insured liabilities in the accompanying consolidated balance sheets. In the opinion of management, the ultimate disposition of claims incurred to date could change; however, we do not expect that these changes would have a material effect on Aurora's consolidated financial position or results of operations. ALA maintains a reinsurance trust account, which in total represents security required by the reinsurance agreement between ALA and the insurance companies. At December 31, 2017 and 2016, assets held in the trust account were \$49.7 million and \$53.8 million, respectively.

Following is a list of corporations and subsidiaries that are included in the accompanying consolidated financial statements. The Obligated Group Members are denoted by an asterisk (\*).

- Aurora Health Care, Inc.\*
- Aurora Health Care Metro, Inc.\* (d/b/a Aurora St. Luke's Medical Center, Aurora St. Luke's South Shore and Aurora Sinai Medical Center)
- West Allis Memorial Hospital, Inc. (d/b/a Aurora West Allis Medical Center)
- Aurora Medical Center of Washington County, Inc.\* (d/b/a Aurora Medical Center Washington County)
- Aurora Medical Center Grafton, LLC\* (d/b/a Aurora Medical Center Grafton)
- BayCare Aurora, LLC (d/b/a Aurora BayCare Medical Center)
- Aurora Health Care North, Inc.\* (d/b/a Aurora Medical Center Manitowoc County)
- Aurora Health Care Central, Inc.\* (d/b/a Aurora Sheboygan Memorial Medical Center)
- Aurora Medical Center of Oshkosh, Inc.\* (d/b/a Aurora Medical Center Oshkosh)
- Aurora Health Care Southern Lakes, Inc.\* (d/b/a Aurora Lakeland Medical Center, Aurora Memorial Hospital of Burlington, Aurora Medical Center Kenosha, and Aurora Medical Center Summit)
- Aurora Psychiatric Hospital, Inc. (d/b/a Aurora Psychiatric Hospital)
- Kradwell School, Inc.
- Aurora Medical Group, Inc.\*
- Midwest Area Physicians, LLC
- AMG Illinois, Ltd.
- Aurora Quick Care, LLC
- Aurora Advanced Healthcare, Inc.
- Visiting Nurse Association of Wisconsin, Inc. (d/b/a Aurora At Home)
- Aurora UW Academic Medical Group, Inc.
- Aurora Family Service, Inc.
- Aurora Health Care Ventures, Inc.
- Lakeshore Medical Clinic, LLC
- Aurora Pharmacy, Inc.
- Diversified Care, Inc.
- Aurora Retail Stores, Inc.
- Advanced Healthcare, Inc.
- East Mequon Surgery Center, LLC
- North Shore Surgical Center
- Aurora Consolidated Laboratories, a Co-Tenancy
- Aurora Research Institute, LLC
- Aurora Health Network, Inc.
- Aurora Accountable Care Organization, LLC
- Aurora Health Care Foundation, Inc.
- Aurora Health Foundation, Inc.
- Vince Lombardi Cancer Foundation, Inc.
- Aurora Liability Assurance, Ltd. (Cayman Island corporation)
- Health Care Re, Ltd. (Cayman Island corporation)
- LMC, Inc.
- Wisconsin Surgery Center, LLC
- The Surgery Center, LLC
- Aurora Surgery Centers, LLC
- Aurora Clinically Integrated Network, LLC

#### **19. AFFILIATION**

In December 2017, Aurora and Advocate Health Care Network ("Advocate") entered into a definitive affiliation agreement (the Agreement) to form Advocate Aurora Health, Inc. The completion of the transaction is conditioned upon the satisfaction of certain conditions precedent. Though Aurora can provide no assurances the transaction will, or will not, occur, Aurora anticipates closing the transaction on or about April 1, 2018.

#### 20. SUBSEQUENT EVENTS

Aurora evaluated events and transactions subsequent to December 31, 2017 through March 29, 2018, the date of financial statement issuance.

In January 2018, Aurora purchased nineteen properties that were previously leased for cash consideration of \$433.0 million. Aurora was obligated under capital lease and financing arrangements entered into in connection with certain leasing and sale-leaseback transactions for eighteen of these properties. The transaction resulted in the realization of deferred gains related to these properties of \$5.7 million. In connection with this transaction, Aurora derecognized \$48.9 million of net capital lease assets and \$78.4 million of capital lease liabilities. The net gain was recorded as a reduction to the carrying value of the properties acquired.

In February 2018, Aurora sold its 50% ownership interest in the Menomonee Falls Ambulatory Surgery Center and its 20% ownership interest in the Froedtert Surgery Center for cash consideration of \$5.0 million and \$2.0 million, respectively. Aurora's investments in the surgery centers were accounted for under the equity method of accounting. Aurora's carrying value in the surgery centers totaled \$5.8 million as of December 31, 2017.

\*\*\*\*